Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07030517 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

Name: A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma — clinical trial record (NCT07030517)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 4

SponsorJohnson & Johnson Private Limited

Started2025-05-22

View on ClinicalTrials.gov ↗

The purpose of this study is to assess the safety of teclistamab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma (RRMM) (that is, a blood cancer that comes back after treatment or does not respond to treatment) who have previously received at least 3 prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor and an anti-cluster of differentiation (CD)38 antibody (is a protein that fights infection) and whose disease have progressed on the last therapy.

Amendment history 2 changes detected by DataLookout

2026-08-29

Completion moved earlier: 2027-06-20 → 2027-02-14

2026-08-01

Enrollment closed, study ongoing

Trial Details

NCT Number	NCT07030517
Lead Sponsor	Johnson & Johnson Private Limited
Conditions	Multiple Myeloma
Enrollment	75 participants
Start Date	2025-05-22
Primary Completion	2026-11-03 (estimated)
Study Completion	2027-02-14 (estimated)
Updated on ClinicalTrials.gov	2026-08-28